Notice Number: NOT-DA-17-003

Key Dates
Release Date: November 8, 2016

Issued by
National Institute on Drug Abuse (NIDA)
National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention (NCHHSTP/CDC)
Center for Substance Abuse Treatment (CSAT/SAMHSA)

Purpose

This Notice is to inform potential applicants to RFA-DA-17-014 "HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States: Building Systems for Prevention, Treatment and Control (UG3/UH3)" and RFA-DA-17-023 "Hepatitis C Virus (HCV) Advanced Molecular Detection in Support of Systems for Prevention, Treatment and Control of HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States (U24)" of a pre-application conference call on Thursday, November 17, 2016.

The intent of the conference call is to provide an overview of the FOAs and to answer questions from potential applicants pertinent to preparing applications. The conference call is optional and not required for submission to RFA-DA-17-014 and RFA-DA-17-023.

The conference call may conclude before the scheduled time depending on the number of questions.

Webinar Information:
Date: Thursday, November 17, 2016
Time: 4:00 p.m. - 5:00 p.m. EST

Persons wishing to receive call-in information for this webinar should contact the NIDA Program Contact, Richard A. Jenkins at [email protected].

Prospective applicants are encouraged to submit their questions or comments regarding the RFAs to [email protected] before November 17, 2016.

Please indicate “Opioid RFA Pre-Application Conference Call” in the subject line of your email.

The email message should contain:

Name,
Institution,
Email address,
Plans to join by internet or by phone.

NIDA staff will post representative questions, and answers to those questions at the current FAQ site for these RFAs: https://www.drugabuse.gov/funding/supplemental-information-nida-rfas-da-17-014-da-17-023. For any additional questions that are not addressed in the summary, please contact the Scientific/Research contact listed in RFA-DA-17-014 and RFA-DA-17-023.

Inquiries

Please direct all inquiries to:

Richard A. Jenkins PhD
National institute on Drug Abuse (NIDA)
Telephone: 301-443-1923 
Email: [email protected]

Walter (Paul) Smutz, PhD
National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention (NCHHSTP)
Telephone: 404-718-8830
Email: [email protected]